Polaryx Therapeutics, Inc. (NasdaqCM: PLYX)
Health Care · Pharmaceuticals · US
$2.06
-20.77% today · -92.6% 1Y
Polaryx Therapeutics, Inc. (NasdaqCM: PLYX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $129.60M and employs 11 people.
Over the last twelve months the share price has lost 92.6%, trading between 1.86 and 48.91.
Tweenvest scores Polaryx Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
PLYX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $129.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.14
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $48.91
- 52-week low
- $1.86
- Avg volume (3M)
- —
- Shares outstanding
- 49.85M
- Employees
- 11
- Next earnings
- —
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
- Founded
- 2014
- Listed since
- Feb 2, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,237.51 | -1.43% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.91 | +0.25% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.23 | -1.52% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.20 | -1.70% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.54 | -1.52% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.93 | -0.50% |
Figures last refreshed Aug 18, 2026.